Immatics (IMTX) Gains from Investment Securities (2020 - 2025)
Immatics (IMTX) posted Gains from Investment Securities of -$150550.6 for Q2 2025, up 91.04% sequentially from -$1.7 million in Q1 2025, and down 121.57% YoY from $697823.1 in Q2 2024.
Analysis
Immatics (IMTX) Gains from Investment Securities (2020 - 2025) Analysis & Trends
Immatics has reported Gains from Investment Securities for 6 years, with the latest figure at -$150550.6 in Q2 2025.
- Quarterly Gains from Investment Securities fell 121.57% year-over-year to -$150550.6 in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$1.8 million (up 90.15% YoY) and the FY2025 annual result came in at -$2.0 million, up 89.54% from the prior year.
- Gains from Investment Securities advanced to -$150550.6 in Q2 2025 per IMTX's latest filing, from -$1.7 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $14.3 million in Q2 2023 and troughed at -$18.5 million in Q1 2022.
- A 5-year average of -$1.1 million and a median of $273636.3 in 2024 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities slumped 1365.71% in 2022, then surged 380.2% in 2023.
- Over 5 years, Gains from Investment Securities stood at $1.8 million in 2021, then tumbled by 270.8% to -$3.1 million in 2022, then slumped by 144.09% to -$7.6 million in 2023, then tumbled by 82.33% to -$13.9 million in 2024, then surged by 98.92% to -$150550.6 in 2025.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$150550.6, -$1.7 million, and -$13.9 million for Q2 2025, Q1 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -150,550.64 |
| Mar 31, 2025 | -1.68 Mn |
| Dec 31, 2024 | -13.93 Mn |
| Sep 30, 2024 | -4.21 Mn |
| Jun 30, 2024 | 697,823.15 |
| Mar 31, 2024 | -1.13 Mn |
| Dec 31, 2023 | -5.41 Mn |
| Sep 30, 2023 | 1.52 Mn |
| Jun 30, 2023 | 14.27 Mn |
| Mar 31, 2023 | -7.94 Mn |
| Dec 31, 2022 | -3.13 Mn |
| Sep 30, 2022 | 5.91 Mn |
| Jun 30, 2022 | 2.97 Mn |
| Mar 31, 2022 | -18.55 Mn |
| Dec 31, 2021 | 1.83 Mn |
| Sep 30, 2021 | 6.43 Mn |
| Jun 30, 2021 | 3.28 Mn |
| Mar 31, 2021 | 1.47 Mn |
| Dec 31, 2020 | -5.51 Mn |